EIGRQ — Eiger Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $14.81m
- $30.49m
- $15.77m
- 37
- 35
- 89
- 53
Annual cashflow statement for Eiger Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -70.3 | -65.1 | -33.9 | -96.8 | -75 |
| Depreciation | |||||
| Non-Cash Items | 6.58 | 7.6 | -36.1 | 13 | 5.87 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.009 | -5.9 | -1.62 | 0.481 | -5.73 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -63.6 | -63.2 | -71.3 | -83 | -74.5 |
| Capital Expenditures | -0.475 | -0.258 | -0.225 | -0.34 | -0.234 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16 | -44.5 | 61.8 | 9.97 | 74.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -16.5 | -44.8 | 61.5 | 9.63 | 74.2 |
| Financing Cash Flow Items | -0.932 | -0.022 | -0.316 | -0.286 | -0.015 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 58.2 | 97.5 | 3.17 | 77 | 0.041 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -21.9 | -10.5 | -6.64 | 3.58 | -0.358 |